Elsevier

Contraception

Volume 84, Issue 4, October 2011, Pages 372-376
Contraception

Original research article
Opportunities missed: improving the rate of contraceptive counseling or provision when prescribing reproductive-aged women potentially teratogenic medications in a family medicine resident clinic

https://doi.org/10.1016/j.contraception.2011.01.024Get rights and content

Abstract

Background

Studies show poor documentation of contraceptive counseling when prescribing women teratogenic medications, suggesting a missed opportunity for contraceptive education.

Study Design

A retrospective chart review of selected Food and Drug Administration class D and X medications evaluated the office visit initiating this medication for documentation of either contraceptive counseling or provision. Following an educational intervention, another retrospective review was conducted to determine if the rate of counseling improved.

Results

The initial rate of documented counseling was 46% and improved to 80% following the educational intervention (p=.0002), an improvement in both overall rate and that seen in the previous year.

Conclusions

This study is the first to document contraceptive counseling rates when providing teratogenic medications in a training setting. It illustrates a need for increased attentiveness in primary care training practices to the risks of teratogenic medications and the need for comprehensive contraceptive counseling. Simple interventions may improve this rate and decrease missed opportunities.

Introduction

Teratogenic medications, from the Latin terato-, meaning “monster,” and –genic, “producing,” are those medications that may cause alteration or malformation during fetal development. Given both medical and ethical considerations, these medications are poorly studied in reproductive-aged women, and information about dose, timing and exact effects on the fetus is often incompletely understood. In an effort to protect reproductive-aged women from potential adverse outcomes such as actual birth defects, but also from concerns about fetal exposure given poorly understood risks, the US Food and Drug Administration (FDA) instituted a lettered safety classification system [1] for all prescription drugs in 1979 (Table 1). Of greatest concern for prescribers, classes D and X are known to be teratogenic. Notably, this lettered system is currently under review and is slated to be changed and refined to more completely educate both patients and providers about the risks of these medications.

Two studies by Schwarz et al. [2], [3] examined the prescription of teratogenic medications largely in the primary care setting along with the associated documentation of contraceptive counseling rates. Using the National Ambulatory Medical Care Survey to examine over 12,000 outpatient visits, the first study determined that the most frequently prescribed class D and X medications included anxiolytics, anticonvulsants, antibiotics and “statins” (HMG-CoA reductase inhibitors) [2]. Prescription of these medications occurred at 1 in every 13 visits for women aged 14–44 years. They further noted that 45% of these prescriptions were given by primary care physicians practicing either family or internal medicine. Contraceptive counseling was documented during less than 20% of the visits and at rates equal to that of women receiving class A, B or C medications. A second study conducted in a large health maintenance organization setting with over 488,000 patients found one in every six women aged 15–44 years filled a prescription for a class D or X medication [3]. They documented near equal rates of contraceptive counseling for women filling class A or B medications (48%) versus class D or X medications (51%). They noted that family and internal medicine practitioners prescribed the greatest proportion of class D and X medications (48%). In rank order, psychiatrists, dermatologists, gynecologists, pediatricians and other subspecialists provided the remainder. These studies suggest that women are not receiving contraceptive counseling at adequate rates to prevent possible adverse outcomes, such as pregnancy termination or potential birth defects from exposure to teratogenic medicines. Appropriate to a larger study volume, rates were calculated by gathering data on prescriptions and contraceptive counseling or provision separately, and then statistically estimated by comparing these proportions [2], [3]. These studies were not practice-based models looking at actual documented rates at the time of prescription.

Family medicine encompasses a distinctive environment of providing prescriptive services across all areas of disease management, in addition to serving its patients' gynecological wellness and preventive health care needs. Family medicine physicians are typically able to provide access to all forms of birth control, including those procedure-related (specifically long-acting reversible contraceptives), unlike the internists, psychiatrists, dermatologists and other specialists included in the previously published work. Our practice is a large family medicine clinic in a community-based residency training program. We serve a 580-bed hospital system and staff a clinic following continuity patients with a population of approximately 18,000. As the largest medical practice in our community, we are staffed by 32 residents and 8 faculty, with both allopathic and osteopathic backgrounds. We serve both a rural and suburban patient population in a small southeastern city in an economically depressed area of our state. We have been using an electronic medical record (EMR) since October 2002.

Documentation of both contraceptive and risks/benefits counseling is critical in forming good prescribing habits among young physicians and also as a medicolegal necessity. Data that interventions help improve counseling rates support the inclusion of education about contraceptive counseling and the effects of teratogenic medications as a routine part of primary care residency training programs. Conducted through residency curriculum to teach and support quality improvement research in health care, the purpose of this study was to increase attentiveness both in our own practice and broadly to all primary care training practices about the risks of teratogenic medications and the need for adequate and comprehensive contraceptive counseling.

Section snippets

Phase 1: data collection

Using the EMR for retrospective chart review, inquiries were run to locate the charts of women of reproductive age taking selected FDA class D and X medications frequently prescribed in the primary care setting. These medications were as follows: paroxetine, methotrexate or warfarin; selected longer-term tetracyclines (minocycline or tetracycline); a benzodiazepine (defined as any medication containing either “azepam” or “azolam”) and any statin (defined as any medication containing “astatin”).

Results

In phase 1, 377 prescriptive encounters in 246 patient charts were reviewed, 265 prescriptive encounters with class D or X medications in 182 patient charts were included for analysis and 112 the met exclusion criteria. The overall rate of contraceptive counseling was found to be 46%. In phase 3, 233 prescriptive encounters with class D or X medications in 199 patient charts were reviewed, 35 prescriptive encounters in 32 patient charts were included for analysis and 198 met the exclusion

Improving counseling rate

The improvement in the documented contraceptive counseling rate over time is likely not entirely due to increased attentiveness to our specific study question, but rather to increased proficiency by the practice as a whole with the EMR. Numerous innovations in the EMR itself over this time period increased ease of charting and facilitated documentation of all aspects of medical record keeping for the practice. In ours, as in all residency practices, providers turn over annually in this 3-year

References (4)

There are more references available in the full text version of this article.

Cited by (19)

  • A Survey of Healthcare Providers About Reproductive Healthcare for Adolescent Women With Epilepsy

    2022, Journal of Pediatric and Adolescent Gynecology
    Citation Excerpt :

    These findings point to a need for improved education around teratogens, as well as for systemic interventions to assist primary care and women's health providers in identifying patients prescribed teratogens who may require contraception. Interventions in adult primary care have identified professional education and clinical decision support tools in the electronic health record as effective strategies to improve SRH care for patients prescribed teratogens.27-29 Limitations of this study include an inability to determine a response rate for this survey.

  • A survey of child neurologists about reproductive healthcare for adolescent women with epilepsy

    2021, Epilepsy and Behavior
    Citation Excerpt :

    Additional interventions may be adapted from efforts of other specialties to improve SRH care provision, as other pediatric and adult specialties have reported similar challenges with SRH care [27–29]. Clinical decision support tools integrated in the electronic health record such as alert systems related to SRH have been effective in other pediatric subspecialty settings, as well as adult primary care [30–34]. Strategies that may merit further exploration include cultivating stronger partnerships between child neurologists and general pediatricians, adolescent medicine specialists and pediatric gynecologists to facilitate collaborative SRH care.

  • Pediatric Subspecialists’ Practices and Attitudes Regarding Sexual and Reproductive Healthcare for Adolescent and Young Adult Women Prescribed Teratogenic Medications

    2021, Journal of Pediatrics
    Citation Excerpt :

    Pediatric subspecialists endorsed all facilitators in the survey as helpful for sexual and reproductive healthcare care, indicating that a variety of interventions might be acceptable. Prior effective interventions have included professional and patient education, EHR clinical decision support tools, and referrals to sexual and reproductive healthcare providers.9,12,15-17 Embedding sexual and reproductive healthcare providers in subspecialty practices might be an opportunity for further research.

  • Contraceptive counseling in reproductive-aged women treated for breast cancer at a tertiary care institution: a retrospective analysis

    2017, Contraception
    Citation Excerpt :

    Our findings indicate that contraceptive counseling and reproductive health services provided to women with cancer are suboptimal. This adds to previous studies that have investigated rates of contraceptive counseling for patients prescribed teratogenic medications, classified as Class D or X drugs, in primary care settings [24–27]. Across studies, rates of contraceptive counseling were suboptimal, ranging from less than 20% to approximately 50% receiving counseling [24–26].

  • Process Evaluation of a Task-Shifting Strategy in Hormonal Contraception: Does Training Translate into Practice?

    2013, Journal of Obstetrics and Gynaecology Canada
    Citation Excerpt :

    According to this cross-sectional study, more than one in two nurses (57.3%) adopted the expected new practice after receiving training in hormonal contraception, a proportion consistent with that found in our exploratory study in 2010 (61.4%).29 In several domains, training does not always translate into practice.38-43 As shown in Honduras, 41 where training in IUD insertion was offered to nurses’ auxiliaries (62% completed the training), a large proportion of those trained did not insert IUDs after returning to their workplaces, mainly because they did not feel confident in their skills.

View all citing articles on Scopus

There was no funding received for this study.

View full text